Physician profile
Caitlin E Pribble
NPI 1689224214
$4,403.60
in general payments reported to CMS, 2019-2025
38 companies · $17.63 in 2025
The $17.63 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,235 · 2022: $1,086 · 2023: $1,721 · 2024: $343 · 2025: $17.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.63 | 2021-2024 | |
| Esperion Therapeutics, INC. | $506.75 | 2021-2024 | Nexletol |
| Amgen INC. | $341.69 | 2021-2024 | Repatha, Otezla |
| Mylan Specialty L.P. | $331.83 | 2021-2024 | Yupelri |
| Lilly USA, LLC | $278.47 | 2021-2023 | Mounjaro, Trulicity, Emgality |
| Sumitomo Pharma America, INC. | $249.82 | 2023-2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $244.93 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $192.39 | 2021-2024 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $166.56 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $143.31 | 2021-2023 | Verquvo, Belsomra |
| Dexcom, INC. | $99.39 | 2021-2023 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $98.26 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $76.51 | 2021-2023 | Rexulti |
| Collegium Pharmaceutical, INC. | $69.14 | 2021-2023 | Xtampza |
| Idorsia Pharmaceuticals US INC | $67.61 | 2023 | Quviviq |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Pribble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.